178 related articles for article (PubMed ID: 20932754)
1. Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents.
Lai Y; Shen L; Zhang Z; Liu W; Zhang Y; Ji H; Tian J
Bioorg Med Chem Lett; 2010 Nov; 20(22):6416-20. PubMed ID: 20932754
[TBL] [Abstract][Full Text] [Related]
2. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Ling Y; Ye X; Zhang Z; Zhang Y; Lai Y; Ji H; Peng S; Tian J
J Med Chem; 2011 May; 54(9):3251-9. PubMed ID: 21504204
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid.
Huang Z; Zhang Y; Zhao L; Jing Y; Lai Y; Zhang L; Guo Q; Yuan S; Zhang J; Chen L; Peng S; Tian J
Org Biomol Chem; 2010 Feb; 8(3):632-9. PubMed ID: 20090981
[TBL] [Abstract][Full Text] [Related]
4. ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways.
Yang L; Ling Y; Zhang Z; Zhao Q; Tang J; Ji H; Zhang Y
Biochem Biophys Res Commun; 2011 Jun; 409(4):752-7. PubMed ID: 21621522
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
Ling Y; Ye X; Ji H; Zhang Y; Lai Y; Peng S; Tian J
Bioorg Med Chem; 2010 May; 18(10):3448-56. PubMed ID: 20435479
[TBL] [Abstract][Full Text] [Related]
6. Glycosylated diazeniumdiolate-based oleanolic acid derivatives: synthesis, in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents.
Huang Z; Fu J; Liu L; Sun Y; Lai Y; Ji H; Knaus EE; Tian J; Zhang Y
Org Biomol Chem; 2012 May; 10(19):3882-91. PubMed ID: 22473516
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents.
Zou ZH; Lan XB; Qian H; Huang WL; Li YM
Bioorg Med Chem Lett; 2011 Oct; 21(19):5934-8. PubMed ID: 21843940
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH
Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524
[TBL] [Abstract][Full Text] [Related]
9. Furoxan nitric oxide donor coupled chrysin derivatives: synthesis and vasculoprotection.
Zou XQ; Peng SM; Hu CP; Tan LF; Deng HW; Li YJ
Bioorg Med Chem Lett; 2011 Feb; 21(4):1222-6. PubMed ID: 21256748
[TBL] [Abstract][Full Text] [Related]
10. Antitumor platinum(II) complexes containing platinum-based moieties of present platinum drugs and furoxan groups as nitric oxide donors: synthesis, DNA interaction, and cytotoxicity.
Zhao J; Gou S; Sun Y; Fang L; Wang Z
Inorg Chem; 2012 Oct; 51(19):10317-24. PubMed ID: 22957695
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid.
Chen L; Zhang Y; Kong X; Lan E; Huang Z; Peng S; Kaufman DL; Tian J
J Med Chem; 2008 Aug; 51(15):4834-8. PubMed ID: 18598019
[TBL] [Abstract][Full Text] [Related]
12. Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies.
Abreu RM; Ferreira IC; Calhelha RC; Lima RT; Vasconcelos MH; Adega F; Chaves R; Queiroz MJ
Eur J Med Chem; 2011 Dec; 46(12):5800-6. PubMed ID: 22014996
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antitumor activity of ring A modified glycyrrhetinic acid derivatives.
Csuk R; Schwarz S; Siewert B; Kluge R; Ströhl D
Eur J Med Chem; 2011 Nov; 46(11):5356-69. PubMed ID: 21959232
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of some antitumor active derivatives from glycyrrhetinic acid.
Csuk R; Schwarz S; Kluge R; Ströhl D
Eur J Med Chem; 2010 Dec; 45(12):5718-23. PubMed ID: 20884085
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents.
Dai M; Yuan X; Kang J; Zhu ZJ; Yue RC; Yuan H; Chen BY; Zhang WD; Liu RH; Sun QY
Eur J Med Chem; 2013 Nov; 69():159-66. PubMed ID: 24013415
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of novel heterocyclic ring-fused 18β-glycyrrhetinic acid derivatives with antitumor and antimetastatic activity.
Gao C; Dai FJ; Cui HW; Peng SH; He Y; Wang X; Yi ZF; Qiu WW
Chem Biol Drug Des; 2014 Aug; 84(2):223-33. PubMed ID: 24612785
[TBL] [Abstract][Full Text] [Related]
17. Glycyrrhetinic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2.
Satomi Y; Nishino H; Shibata S
Anticancer Res; 2005; 25(6B):4043-7. PubMed ID: 16309197
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of triazole linked glycosylated 18β-glycyrrhetinic acid derivatives as anticancer agents.
Parida PK; Sau A; Ghosh T; Jana K; Biswas K; Raha S; Misra AK
Bioorg Med Chem Lett; 2014 Aug; 24(16):3865-8. PubMed ID: 25027936
[TBL] [Abstract][Full Text] [Related]
19. Conversions at C-30 of glycyrrhetinic acid and their impact on antitumor activity.
Csuk R; Schwarz S; Siewert B; Kluge R; Ströhl D
Arch Pharm (Weinheim); 2012 Mar; 345(3):223-30. PubMed ID: 21997717
[TBL] [Abstract][Full Text] [Related]
20. Improvement of the cytotoxicity and tumor selectivity of glycyrrhetinic acid by derivatization with bifunctional amino acids.
Csuk R; Schwarz S; Kluge R; Ströhl D
Arch Pharm (Weinheim); 2011 Aug; 344(8):505-13. PubMed ID: 21674592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
